Last updated: August 17, 2026
LIVMARLI, Mirum Pharmaceuticals' oral maralixibat solution, has become the company's principal commercial asset and a leading treatment for rare pediatric cholestatic liver diseases. Revenue growth is driven by two U.S. indications, chronic treatment duration, international expansion, and high-value specialty-drug reimbursement. The main commercial constraints are small diagnosed populations, payer authorization requirements, adverse gastrointestinal effects, and competition from Bylvay.
Mirum reported approximately $229 million in LIVMARLI net product revenue in 2023, with total company product revenue of roughly $264 million when Cholbam is included. The product's near-term growth path depends more on patient identification, global reimbursement, and label expansion than on broad primary-care adoption. Its patent and regulatory exclusivity position supports a multiyear commercial window, although generic and competing bile-acid transporter inhibitor risk will increase as regulatory exclusivities expire.
What is LIVMARLI and which diseases does it treat?
LIVMARLI is a prescription oral solution containing maralixibat chloride, an ileal bile acid transporter, or IBAT, inhibitor. It reduces bile acid reabsorption in the ileum, increasing fecal bile acid excretion and lowering systemic bile acid exposure.
The U.S. Food and Drug Administration approved LIVMARLI for:
| Indication |
FDA approval |
Approved population |
| Alagille syndrome-associated cholestatic pruritus |
September 2021 |
Patients at least 1 year old |
| Progressive familial intrahepatic cholestasis, or PFIC, |
May 2023 |
Patients at least 1 year old |
The 2021 approval was for Alagille syndrome, not PFIC. Mirum later secured FDA approval for PFIC based on clinical data showing reductions in pruritus and serum bile acids. The product was initially approved for patients at least 1 year old and later received a lower-age expansion for Alagille syndrome in the United States. [1][2]
LIVMARLI is positioned as a chronic treatment for pediatric patients with severe cholestatic disease. Its commercial value comes from a high annual treatment cost, specialist prescribing, and a concentrated prescriber base in pediatric hepatology centers.
How large is the LIVMARLI market?
The addressable market is a rare-disease market with a limited number of patients but high treatment value per patient.
Alagille syndrome market
Alagille syndrome is a genetic disorder involving bile duct paucity and multisystem disease. Cholestatic pruritus can be severe and may cause sleep disruption, impaired daily functioning, skin injury, and consideration of surgical or transplant interventions.
The commercial market is constrained by:
- Low disease prevalence.
- Delayed or missed diagnosis.
- Variation in disease severity.
- Use of liver transplantation in advanced cases.
- Need for genetic and hepatology evaluation.
- Payer documentation requirements.
LIVMARLI's approval gives Mirum access to a defined pediatric population with a severe symptom burden and few approved pharmacologic alternatives.
PFIC market
PFIC comprises several genetic disorders that impair bile formation and cause progressive liver disease. The disease is heterogeneous, and treatment response can vary by genetic subtype.
The PFIC market has a broader competitive field than the Alagille market because Bylvay, marketed by Ipsen, is also approved in the United States for PFIC. Surgical biliary diversion and liver transplantation remain important options for selected patients.
The commercial opportunity is affected by genetic testing rates, the ability to identify patients before advanced liver damage, and payer policies governing treatment continuation.
How has LIVMARLI revenue developed?
LIVMARLI has produced rapid revenue growth since U.S. launch. The trajectory reflects indication expansion and increased patient enrollment rather than broad-volume pharmaceutical distribution.
| Period |
LIVMARLI commercial development |
Financial implication |
| 2021 |
U.S. Alagille syndrome approval |
Launch and early access period |
| 2022 |
Initial commercial scaling; international regulatory progress |
Growth from a small base |
| 2023 |
PFIC approval and broader U.S. prescribing |
Major expansion of patient opportunity |
| 2024 onward |
Continued U.S. penetration and international commercialization |
Growth increasingly dependent on diagnosis, reimbursement, and geographic execution |
Mirum reported LIVMARLI net product revenue of approximately $228.7 million for 2023. Total product revenue, including Cholbam, was approximately $263.8 million. LIVMARLI accounted for the overwhelming majority of Mirum's commercial revenue and became the company's primary financial engine. [3]
The product's revenue model has several characteristics:
- High revenue per treated patient.
- Specialty pharmacy and specialty-distribution economics.
- Relatively low unit volume.
- Revenue concentration in the United States.
- High sensitivity to reimbursement approvals and patient persistence.
- Potential for operating leverage as commercial infrastructure matures.
Mirum's financial trajectory therefore differs from that of a conventional primary-care drug. The company does not need millions of patients to produce meaningful revenue. It does need sustained access to a relatively small population, reliable diagnosis, and durable payer coverage.
What drives LIVMARLI market growth?
Label expansion
The PFIC approval materially increased LIVMARLI's addressable population and reduced reliance on a single indication. Label expansion is strategically important because the same formulation, specialty sales organization, and hepatology infrastructure can support both diseases.
Patient identification
Rare-disease commercial growth depends on finding undiagnosed patients. Mirum can increase treated-patient numbers through:
- Genetic testing.
- Referral to pediatric liver centers.
- Disease-awareness programs.
- Screening of children with persistent cholestasis.
- Earlier intervention before transplant evaluation.
- International partnerships and local regulatory approvals.
Patient finding is a long-term growth lever, but it also creates a slower commercial ramp than the launch of a broad-market drug.
Chronic treatment
Patients who respond and remain eligible may use LIVMARLI for extended periods. Chronic use increases lifetime revenue per patient and makes patient persistence a central commercial metric.
Treatment duration can be reduced by liver transplantation, inadequate response, intolerance, disease progression, or payer discontinuation. Mirum's commercial performance therefore depends on both new patient starts and continuation rates.
International commercialization
Mirum has pursued approvals and commercial access outside the United States, including European markets. International expansion can increase revenue but generally produces lower net pricing than the United States and requires country-specific reimbursement negotiations.
The main international barriers are:
- Health technology assessment requirements.
- National price controls.
- Small-country patient populations.
- Local distribution costs.
- Delayed diagnosis.
- Different treatment guidelines.
- Currency fluctuations.
How does LIVMARLI compare with Bylvay?
Bylvay, containing odevixibat, is the most direct commercial comparator. Both drugs inhibit the ileal bile acid transporter and target rare pediatric cholestatic liver diseases.
| Factor |
LIVMARLI |
Bylvay |
| Active ingredient |
Maralixibat |
Odevixibat |
| Company |
Mirum Pharmaceuticals |
Ipsen |
| U.S. Alagille indication |
Yes |
No, based on current approved positioning |
| U.S. PFIC indication |
Yes |
Yes |
| Administration |
Oral solution |
Oral formulation, including pellets and capsules depending on market |
| Core commercial market |
Alagille syndrome and PFIC |
PFIC and other approved cholestatic indications by jurisdiction |
| Competitive advantage |
Two major U.S. pediatric indications and established Alagille positioning |
Broader international presence and competing PFIC platform |
| Key risk |
Small population and reimbursement concentration |
Direct competition in PFIC and indication-specific pricing pressure |
The competitive contest is not determined only by clinical efficacy. Prescriber familiarity, formulation convenience, age eligibility, payer policies, patient response, adverse-event management, and distribution reliability can affect market share.
LIVMARLI's strongest differentiation is its U.S. Alagille franchise. PFIC is more competitive because Bylvay has an approved presence in the same disease area. The two products may compete for newly diagnosed patients, treatment-switching patients, and patients with incomplete response or tolerability problems.
What is the FDA regulatory and Orange Book status of LIVMARLI?
LIVMARLI is approved under FDA NDA 214662. FDA regulatory exclusivity is separate from patent protection.
Regulatory exclusivity timeline
| Protection |
Relevant date |
Expected end |
| Alagille syndrome orphan-drug exclusivity |
September 2021 approval |
Approximately September 2028 |
| PFIC orphan-drug exclusivity |
May 2023 approval |
Approximately May 2030 |
| New chemical entity exclusivity, if applicable to the approved NDA |
Based on original approval date |
Runs independently from indication-specific orphan exclusivity |
| Patent protection |
Patent-specific |
Extends beyond regulatory exclusivity for certain claims |
Orphan-drug exclusivity generally prevents FDA approval of the same drug for the same disease or condition for seven years, subject to statutory exceptions. It does not block all competing drugs, including products with different active ingredients. It also does not prevent patent challenges or approval of a clinically superior product in certain circumstances. [4]
LIVMARLI's Orange Book position should be evaluated using the current FDA Orange Book, because listed patents, delisting activity, and regulatory exclusivity can change. The relevant analysis is whether a generic applicant can file an ANDA referencing the oral solution and whether the applicant must make a Paragraph IV certification against listed patents.
The practical generic risk is limited in the near term by:
- Orphan-drug exclusivity for the approved indications.
- Patent claims covering maralixibat formulations or treatment methods.
- The small commercial volume relative to development costs.
- The complexity of demonstrating pharmaceutical equivalence for an oral solution.
- Potential regulatory barriers involving indication carve-outs.
What patents protect LIVMARLI?
Mirum's patent estate is directed to maralixibat, compositions, pharmaceutical formulations, and methods for treating cholestatic diseases. Patent protection should be separated into three categories.
Active-ingredient and composition patents
These patents can cover maralixibat itself, salts, crystalline forms, or pharmaceutical compositions. Their value depends on claim scope, validity, enforceability, and whether a generic formulation can design around the claims.
Formulation patents
LIVMARLI is an oral solution. Formulation claims may cover concentration, excipients, stability, palatability, delivery, and use in pediatric patients. Formulation patents can be commercially important even when the core active-ingredient patent is approaching expiration.
Method-of-use patents
Method claims may cover treatment of Alagille syndrome, PFIC, cholestatic pruritus, or related clinical endpoints. These patents can support a skinny-label strategy if generic applicants seek approval for nonprotected indications, although enforcement against induced infringement can be fact-intensive.
Mirum has disclosed issued and pending U.S. and international patents related to maralixibat and its use. Company filings have described patent protection extending into the 2030s, subject to patent-term adjustment, terminal disclaimers, validity challenges, and jurisdiction-specific expiration dates. [3]
When does LIVMARLI lose exclusivity?
The earliest meaningful loss-of-exclusivity date depends on the type of protection being analyzed.
Regulatory loss of exclusivity
Alagille orphan exclusivity began with the September 2021 approval and generally runs for seven years. PFIC exclusivity runs from the PFIC approval date. A generic company cannot rely on orphan exclusivity alone to launch a different active ingredient, but the protection raises the barrier to a same-drug approval for the protected indication.
Patent loss of exclusivity
Patent expiry may occur later than orphan exclusivity. The relevant date depends on the specific patent and claim. Patent-term adjustment may extend the term beyond the standard 20-year calculation from the earliest effective nonprovisional filing date.
A credible launch forecast must model:
- Earliest ANDA filing date.
- Paragraph IV litigation.
- Thirty-month stay.
- Patent-term adjustment.
- Pediatric exclusivity.
- Settlement terms.
- Indication carve-outs.
- State-law substitution and formulary access.
A generic launch shortly after regulatory exclusivity would not necessarily produce an immediate collapse in LIVMARLI revenue. Rare-disease products often retain substantial branded share because of specialist prescribing, patient support, payer contracts, and limited generic manufacturing capacity.
Which companies are challenging LIVMARLI?
The most significant competitive company is Ipsen, through Bylvay. Bylvay is a direct pharmacologic competitor in PFIC and has a separate international regulatory footprint.
Generic manufacturers are potential future challengers, but the commercial case is less straightforward than for a high-volume tablet. A generic company would need to assess:
- Whether the reference product has an available ANDA pathway.
- Orange Book-listed patents.
- Pediatric dosing and labeling.
- Oral-solution manufacturing.
- Stability and taste requirements.
- Small patient volume.
- Reimbursement and distribution economics.
There is no biosimilar pathway for LIVMARLI. Maralixibat is a small molecule, not a biologic. The relevant future challenge would be an ANDA or another small-molecule regulatory pathway, not a 351(k) biosimilar application.
What litigation and settlement risks affect LIVMARLI?
Patent litigation risk would most likely arise after an ANDA applicant submits a Paragraph IV certification against a listed patent. If Mirum sues within the statutory period, FDA approval may be subject to a 30-month stay, subject to litigation outcomes and statutory exceptions.
The principal litigation issues would include:
- Validity of formulation claims.
- Obviousness of maralixibat compositions.
- Written description and enablement.
- Anticipation by earlier IBAT inhibitor disclosures.
- Infringement by alternative excipients or concentrations.
- Induced infringement of method-of-use claims.
- Whether a generic label adequately carves out protected uses.
No settlement agreement should be assumed without a publicly disclosed court filing, SEC disclosure, or FDA-related record. For investors and licensing counterparties, settlement timing can be more important than the nominal patent expiry because an authorized generic or delayed-entry agreement can determine the actual market-entry date.
How strong is the LIVMARLI patent estate?
The estate has strategic strength because it combines regulatory exclusivity with multiple patent categories and a specialized formulation. Its main strengths are:
- Two rare-disease indications.
- Pediatric dosing and administration requirements.
- Oral-solution formulation complexity.
- Potential method-of-use claims.
- Commercial concentration in specialist centers.
- High switching friction for stable patients.
Its vulnerabilities are:
- Small-molecule active ingredient.
- Potential prior-art challenges involving IBAT inhibitors.
- Possibility of formulation design-around.
- Limited absolute market size, which can justify early generic entry.
- Dependence on claim-by-claim enforcement.
- Different patent outcomes across the United States, Europe, and other jurisdictions.
The estate is commercially meaningful but should not be valued as an impenetrable barrier. The strongest protection is likely the combined effect of patents, orphan exclusivity, physician concentration, and patient-support infrastructure.
What is the revenue exposure to LIVMARLI?
LIVMARLI represents Mirum's central revenue exposure. This concentration creates operating leverage but also increases product-specific risk.
Upside factors
- Continued growth in U.S. Alagille adoption.
- PFIC patient additions.
- International reimbursement.
- Increased genetic diagnosis.
- Expansion into additional cholestatic diseases.
- Longer treatment persistence.
- Improved gross margin as revenue scales.
Downside factors
- Payer restrictions.
- Treatment discontinuation.
- Unexpected safety or tolerability findings.
- Competitive switching to Bylvay.
- Slower international uptake.
- Clinical failures in adjacent indications.
- Earlier-than-expected generic entry.
- Dependence on a narrow specialist prescriber base.
The business has a high gross-margin profile typical of specialty pharmaceuticals, but Mirum also carries substantial research, commercial, regulatory, and patient-support costs. Revenue growth therefore does not translate automatically into near-term profitability. The financial trajectory depends on the point at which LIVMARLI's incremental gross profit exceeds ongoing development and commercialization investment.
What generic launch scenarios exist for LIVMARLI?
| Scenario |
Timing |
Commercial effect |
| No early Paragraph IV challenge |
After key regulatory and patent protections |
Mirum retains high share through the protected period |
| Paragraph IV filing with litigation |
FDA approval delayed by litigation or settlement |
Entry date depends on court result or negotiated launch |
| Skinny-label generic |
Entry limited to unprotected indications |
Initial impact may be concentrated in selected patients |
| Authorized generic or settlement entry |
Agreed launch before full patent expiry |
Revenue erosion may begin earlier but follow a managed schedule |
| Multiple generic entrants |
After broad patent and exclusivity expiry |
Greater price pressure and faster share loss |
For a rare pediatric therapy, substitution may be slower than for a mass-market generic because clinicians may prefer the branded product, payers may require prior authorization, and pharmacies may face limited generic supply.
Key Takeaways
- LIVMARLI is Mirum Pharmaceuticals' main commercial product and its primary revenue driver.
- The product has FDA approvals for Alagille syndrome and PFIC, creating a two-indication U.S. franchise.
- Mirum reported approximately $229 million in LIVMARLI revenue in 2023.
- Growth depends on patient identification, specialty reimbursement, treatment persistence, and international access.
- Bylvay is the principal direct competitor, especially in PFIC.
- LIVMARLI has no biosimilar risk because maralixibat is a small molecule.
- Future generic risk will depend on Orange Book patents, Paragraph IV litigation, formulation claims, and settlement terms.
- Patent protection is reported to extend into the 2030s, but specific expiration dates must be assessed patent by patent.
- Revenue concentration creates strong operating leverage but exposes Mirum to product-specific clinical, reimbursement, and competitive risks.
- The most important commercial question is whether Mirum can expand the diagnosed and treated population faster than competition and exclusivity erosion reduce pricing power.
FAQs
Is LIVMARLI a biologic or a small-molecule drug?
LIVMARLI is a small-molecule drug containing maralixibat chloride. It is not a biologic and is not subject to the FDA biosimilar pathway.
Does LIVMARLI compete with Bylvay?
Yes. LIVMARLI and Bylvay are both IBAT inhibitors and compete directly in PFIC. LIVMARLI has a distinct U.S. commercial position in Alagille syndrome.
What is the main revenue risk for Mirum Pharmaceuticals?
The main risk is concentration in LIVMARLI. A change in reimbursement, patient persistence, safety, competitive share, or patent timing can materially affect Mirum's consolidated financial performance.
Can a generic company launch LIVMARLI before patent expiry?
A generic company may challenge listed patents through a Paragraph IV certification. Launch may occur before patent expiry only if the generic prevails in litigation, obtains a favorable settlement, launches at risk, or relies on a pathway that avoids the relevant protected indication or claim.
What is the most important indicator of future LIVMARLI growth?
The most useful operating indicators are new patient starts, treated-patient count, refill persistence, payer approval rates, PFIC adoption, international reimbursement, and quarterly LIVMARLI net product revenue.
References
- U.S. Food and Drug Administration. (2021). FDA approves first drug to treat severe itching in patients with Alagille syndrome. https://www.fda.gov
- U.S. Food and Drug Administration. (2023). FDA approves drug to treat progressive familial intrahepatic cholestasis. https://www.fda.gov
- Mirum Pharmaceuticals, Inc. (2024). Annual report on Form 10-K for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission. https://www.sec.gov
- U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
- Mirum Pharmaceuticals, Inc. (2024). Fourth-quarter and full-year 2023 financial results. https://ir.mirumpharma.com
